BioCentury
ARTICLE | Company News

Map Pharmaceuticals, Allergan deal

March 11, 2013 7:00 AM UTC

Allergan completed its acquisition of Map for $25 per share in cash. Allergan paid Map a total value of about $961 million, plus transaction fees and expenses. Map is now a wholly-owned subsidiary of ...